ArticleCancer chemotherapy and pharmacology2026
Biological frailty and chemotherapy dose intensity independently predict survival in older adults with Stage II-III colon cancer.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the prognostic impact of chemotherapy dose intensity and frailty indices-including the laboratory-based Frailty Index (FI-Lab)-on survival in older adults with stage II-III colon cancer receiving adjuvant chemotherapy.
methodsThis retrospective study included 94 patients aged ≥ 65 years with stage II (high-risk) or stage III colon cancer treated with adjuvant chemotherapy after curative surgery. Frailty was assessed using FI-Lab with a predefined cut-off of 0.25. Measures included the G8 geriatric screening tool, modified 5-item Frailty Index (mFI-5), and Charlson Comorbidity Index (CCI). Patients were categorised as optimal dose completed, optimal dose started with subsequent reduction, or not started at the optimal dose. Overall survival (OS) and disease-free survival (DFS) were analysed using Kaplan-Meier and Cox regression models.
resultsWith a median follow-up of 70 months, 28 recurrences (29.8%) and 22 deaths (23.4%) occurred. FI-Lab ≥ 0.25 independently predicted inferior OS (HR: 3.73; p = 0.023) and DFS (HR: 2.81; p = 0.029). G8, mFI-5, and CCI were not independently associated with survival. Dose initiation strategy was also independently associated with outcomes. Compared with the optimal dose completed group, patients not started at the optimal dose had worse OS (HR: 14.41; p = 0.011) and DFS (HR: 5.16; p = 0.013), whereas dose reduction after optimal initiation was not associated with survival.
conclusionsLaboratory-based frailty and initial dose intensity independently predicted survival in older adults receiving adjuvant chemotherapy for colon cancer. These findings support individualised treatment strategies integrating biological reserve and early treatment intensity.
Indexed as
Identifiers
42909624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.